Literature DB >> 3801275

Menopausal oestrogens and breast cancer risk: an expanded case-control study.

L A Brinton, R Hoover, J F Fraumeni.   

Abstract

A study among 1960 post-menopausal breast cancer cases and 2258 controls identified through a nation-wide screening program enabled evaluation of effects of oestrogen use on breast cancer risk. Ever use was not associated with increased risk (RR = 1.0), but a significant trend was observed with increasing years of use, with users of 20 or more years being at a 50% excess risk. Elevations associated with long-term use were apparent across all menopause subgroups (natural, ovaries retained, ovaries removed). Hormones exerted particularly adverse effects in those initiating use subsequent to a diagnosis of benign breast disease, particularly long-term users (RR = 3.0, 95% CI 1.6-5.5). There was also some indication that effects predominated among the lower stage tumours, an observation similar to that observed for endometrial cancer. These findings support a role for oestrogens in the aetiology of breast cancer, although risk appears to be enhanced only after extended periods of use, and not to the extent observed for other hormonally-sensitive tumours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801275      PMCID: PMC2001552          DOI: 10.1038/bjc.1986.246

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Patterns and determinants of conjugated estrogen use.

Authors:  L Rosenberg; S Shapiro; D W Kaufman; D Slone; O S Miettinen; P D Stolley
Journal:  Am J Epidemiol       Date:  1979-06       Impact factor: 4.897

2.  Menopause and breast cancer risk.

Authors:  D Trichopoulos; B MacMahon; P Cole
Journal:  J Natl Cancer Inst       Date:  1972-03       Impact factor: 13.506

3.  The association of replacement estrogens with breast cancer.

Authors:  A M Nomura; L N Kolonel; T Hirohata; J Lee
Journal:  Int J Cancer       Date:  1986-01-15       Impact factor: 7.396

4.  Oral contraceptive use: association with frequency of hospitalization and chronic disease risk indicators.

Authors:  R Hoover; C Bain; P Cole; B MacMahon
Journal:  Am J Public Health       Date:  1978-04       Impact factor: 9.308

5.  A case-control study of menopausal estrogen therapy and breast cancer.

Authors:  R K Ross; A Paganini-Hill; V R Gerkins; T M Mack; R Pfeffer; M Arthur; B E Henderson
Journal:  JAMA       Date:  1980-04-25       Impact factor: 56.272

6.  A computer program for the analysis of matched case-control studies.

Authors:  J H Lubin
Journal:  Comput Biomed Res       Date:  1981-04

7.  Replacement estrogens and breast cancer.

Authors:  H Jick; A M Walker; R N Watkins; D C D'Ewart; J R Hunter; A Danford; S Madsen; B J Dinan; K J Rothman
Journal:  Am J Epidemiol       Date:  1980-11       Impact factor: 4.897

8.  Exogenous estrogens and other factors in the epidemiology of breast cancer.

Authors:  J L Kelsey; D B Fischer; T R Holford; V A LiVoisi; E D Mostow; I S Goldenberg; C White
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

9.  An epidemiological study of oral contraceptives and breast cancer.

Authors:  M P Vessey; R Doll; K Jones; K McPherson; D Yeates
Journal:  Br Med J       Date:  1979-06-30

10.  Menopausal estrogen use and risk of breast cancer.

Authors:  L A Brinton; R N Hoover; M Szklo; J F Fraumeni
Journal:  Cancer       Date:  1981-05-15       Impact factor: 6.860

View more
  40 in total

1.  Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry.

Authors:  J Embrechts; F Lemière; W Van Dongen; E L Esmans; P Buytaert; E Van Marck; M Kockx; A Makar
Journal:  J Am Soc Mass Spectrom       Date:  2003-05       Impact factor: 3.109

2.  Noncontraceptive hormone use and risk of breast cancer.

Authors:  C P Yang; J R Daling; P R Band; R P Gallagher; E White; N S Weiss
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 3.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 4.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 5.  Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  R H Foster; J A Balfour
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

6.  Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study.

Authors:  Lisa Calvocoressi; Meredith H Stowe; Darryl Carter; Elizabeth B Claus
Journal:  Cancer Epidemiol       Date:  2012-02-06       Impact factor: 2.984

7.  Osteoporosis--an opportunity to prevent being missed.

Authors:  A D Woolf
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

8.  Panel Summary.

Authors:  Lawrence E Shulman
Journal:  Public Health Rep       Date:  1989-09       Impact factor: 2.792

Review 9.  The risks and benefits of long-term estrogen replacement therapy.

Authors:  E L Barrett-Connor
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

10.  Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.

Authors:  D B Willis; E E Calle; H L Miracle-McMahill; C W Heath
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.